U.S. FDA flags five issues at Zydus plant in Ahmedabad

U.S. Food and Drug Administration issued five observations after inspecting Zydus Lifesciences' manufacturing facility in Moraiya, Ahmedabad. The inspection ran from Oct 5 to Oct 13 and concluded with the five observations. Zydus Lifesciences said it will work closely with the FDA to address the observations quickly. The FDA observations were released on Oct 14, 2026, per a statement from the company. The plant produces pharmaceutical products for domestic and export markets.

Context

The FDA inspections aim to ensure that overseas drug manufacturers meet U.S. safety standards, which can affect a company's ability to sell products in the American market.